Byfavo®: A Short-Acting Sedative for Procedures 30 Minutes or Less
Rapid Onset of Action
Onset of sedative effects of 1.0-1.5 minutes1,* and median time to peak sedation was 3.0-3.5 minutes after initial 5 mg dose.2
Rapid Offset of Action
Median time to fully alert was 11.0-14.0 minutes following last dose.2
Rapidly Metabolized
CYP450-independent metabolism with no active metabolite resulting in a terminal half-life of 37-53 minutes.2
The soft drug approach is a strategy where compounds are specifically designed to be vulnerable to rapid biotransformation into inactive metabolites.3,5
Mechanism of Action
Byfavo is a benzodiazepine. Like other benzodiazepines, Byfavo binds to GABAA receptors in the brain, while its carboxylic acid metabolite (CNS7054) has a 300 times lower affinity for the receptor. Byfavo, like other benzodiazepines, did not show clear selectivity between subtypes of the GABAA receptor.2
Soft, Ester-Based Drug Design
Remimazolam was derived from midazolam.3 The molecular structure of remimazolam differs from midazolam, and all other benzodiazepines, due to the addition of the carboxylic ester linkage.4 The addition of a carboxylic ester linkage creates a “soft drug.”5 The soft drug approach is a strategy where compounds are specifically designed to be vulnerable to rapid biotransformation into inactive metabolites.3,5 This approach was used for the development of remifentanil, a nonhepatically metabolized fentanyl derivative.5,6
Characteristic Benzodiazepine Safety Profile
Established Safety in a Diverse Range of Adult Patients Across 3 Clinical Trials
Common Adverse Reactions Occurring at >2% in Any Treatment Group
Data reflect exposure to Byfavo in 630 ASA I-IV patients pooled from the three placebo-controlled Phase 3 studies.1
The most common adverse reactions (>10%) in patients receiving Byfavo for procedural sedation were hypotension, hypertension, diastolic hypertension, systolic hypertension, hypoxia, and diastolic hypotension1
Patients receiving Byfavo experienced less hypotension than those receiving placebo with midazolam1
https://byfavo.com/dosing-and-administration/